(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Condition(s):Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer; HER2-negative Breast CancerLast Updated:January 29, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer; HER2-negative Breast CancerLast Updated:January 29, 2024Recruiting
Condition(s):HR+/HER2- Breast CancerLast Updated:February 21, 2023Recruiting
Condition(s):Hormone Receptor Positive HER-2 Negative Breast CancerLast Updated:September 28, 2021Completed
Condition(s):Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer; PIK3CA Mutant Metastatic Breast CancerLast Updated:February 7, 2024Recruiting
Condition(s):Breast CancerLast Updated:January 21, 2020Completed
Condition(s):Hormone Receptor Positive HER-2 Negative Breast CancerLast Updated:June 15, 2023Recruiting
Condition(s):Advanced Breast Cancer; Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast CancerLast Updated:January 2, 2024Recruiting
Condition(s):HER2-negative Breast CancerLast Updated:July 3, 2023Recruiting
Condition(s):Breast CancerLast Updated:September 21, 2023Active, not recruiting
Condition(s):ER-Positive, HER2-Negative Breast CancerLast Updated:November 16, 2021Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.